BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 33454891)

  • 1. Neurotoxicities associated with immune checkpoint inhibitor therapy.
    Duong SL; Barbiero FJ; Nowak RJ; Baehring JM
    J Neurooncol; 2021 Apr; 152(2):265-277. PubMed ID: 33454891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience.
    Wei D; Zhou DJ; Datta P; Taraschenko O
    Cancer Med; 2021 May; 10(9):2978-2986. PubMed ID: 33660430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
    Vogrig A; Fouret M; Joubert B; Picard G; Rogemond V; Pinto AL; Muñiz-Castrillo S; Roger M; Raimbourg J; Dayen C; Grignou L; Pallix-Guyot M; Lannoy J; Ducray F; Desestret V; Psimaras D; Honnorat J
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system complications associated with immune checkpoint inhibitors.
    Vogrig A; Muñiz-Castrillo S; Joubert B; Picard G; Rogemond V; Marchal C; Chiappa AM; Chanson E; Skowron F; Leblanc A; Ducray F; Honnorat J
    J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):772-778. PubMed ID: 32312871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
    Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
    Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
    Isidro RA; Ruan AB; Gannarapu S; Raj D; Rahma O; Grover S; Srivastava A
    Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
    Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
    JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials.
    Bruna J; Argyriou AA; Anastopoulou GG; Alemany M; Nadal E; Kalofonou F; Piulats JM; Simó M; Velasco R; Kalofonos HP
    J Peripher Nerv Syst; 2020 Jun; 25(2):171-177. PubMed ID: 32166812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurologic complications of immune checkpoint inhibitors.
    Haugh AM; Probasco JC; Johnson DB
    Expert Opin Drug Saf; 2020 Apr; 19(4):479-488. PubMed ID: 32126176
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
    Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
    Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort.
    Kotwal A; Rouleau SG; Dasari S; Kottschade L; Ryder M; Kudva YC; Markovic S; Erickson D
    J Investig Med; 2022 Apr; 70(4):939-946. PubMed ID: 34969937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
    Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
    Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
    Kitagataya T; Suda G; Nagashima K; Katsurada T; Yamamoto K; Kimura M; Maehara O; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Komatsu Y; Hata H; Takeuchi S; Abe T; Sakakibara-Konishi J; Teshima T; Homma A; Sakamoto N
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1782-1788. PubMed ID: 32187734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond T cell toxicity - Intrathecal chemokine CXCL13 indicating B cell involvement in immune-related adverse events following checkpoint inhibition: A two-case series and literature review.
    Otto F; Seiberl M; Bieler L; Moser T; Kleindienst W; Wallner-Essl W; Koelblinger P; Wipfler P; Harrer A
    Eur J Neurol; 2024 Jul; 31(7):e16279. PubMed ID: 38556899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
    Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
    Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitor-related Guillain-Barré Syndrome: A Case Series and Review of the Literature.
    Janssen JBE; Leow TYS; Herbschleb KH; Gijtenbeek JMM; Boers-Sonderen MJ; Gerritsen WR; Westdorp H
    J Immunother; 2021 Sep; 44(7):276-282. PubMed ID: 33758147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database.
    Tang Q; Han Y; Song M; Peng J; Zhang M; Ren X; Sun H
    Medicine (Baltimore); 2024 Mar; 103(13):e37587. PubMed ID: 38552079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.